LOS ANGELES, Oct. 11, 2024 – Glancy Prongay & Murray LLP (“GPM”) announces that investors with substantial losses have the opportunity to lead the securities fraud class action lawsuit against Outset Medical, Inc. (“Outset Medical” or the “Company”) OM. Understanding the Lawsuit Class Period: August 1, 2022 – August 7, 2024 Lead Plaintiff Deadline: October … Read more

Unveiling the Future: Two Stocks to Outpace Nvidia’s Growth by 2030

Russ Cohen

Stagnation on Nvidia’s Horizon As Wall Street’s bull run hits two years, the impact of AI technology on equity success stands out. The potential of self-learning AI systems has sparked Nvidia’s staggering market growth. Since 2023, Nvidia’s stock and market cap have soared, but such parabolic momentum usually wanes. History rings alarm bells—technology hypes often … Read more

Undervalued Gems in the Utilities Sector Undervalued Gems in the Utilities Sector

Russ Cohen

Investors, brace yourselves! The oversold stocks in the utilities sector are creating a compelling opportunity – a chance to dive into undervalued companies at bargain prices. One can gauge the potential of these stocks through the Relative Strength Index (RSI). This momentum indicator, comparing a stock’s strength on up-days to down-days, offers traders a glimpse … Read more

Most Popular

Growth Potential: A Deep Dive into a Recovering Alibaba Stock The Recovery of a Chinese Giant: Alibaba Stock Analysis

Russ Cohen

Alibaba (NYSE: BABA) has long been seen as a flagship of China’s financial landscape, with its fingers in various pies spanning e-commerce, cloud services, and more. Over the past vibrant decade, Alibaba exhibited exponential growth, mesmerizing investors with its upward trajectory. However, its recent stock performance paints a different picture, plummeting by a whopping 63% … Read more

Most Popular

Unveiling China’s Stimulus Rollercoaster at a 17% Bargain

Russ Cohen

As we gaze upon the chart displayed below, the initial assumption might sway towards the recent performance of a tech titan like NVIDIA or a biopharmaceutical entity basking in the glory of a ground-breaking treatment: A Non-Tech Narrative—The “Bland” Index Fund Saga But reality betrays the assumption. The chart in focus is that of the … Read more